OraSure Technologies, Inc

OraSure Technologies is a U.S.-based diagnostics and specimen-collection company that develops, manufactures, markets, and sells rapid tests and related collection devices. Its portfolio includes oral-fluid and other in vitro diagnostic tests, HIV and hepatitis self-tests, and sample management products used across clinical, public health, research, and commercial settings.

−53,7 %

41,9 %

−59,8 %

−38,1 %

6.58

5.80

— OraSure Technologies, Inc
%
Diagnostics - Professional58% Rapid diagnostic tests sold to healthcare and public health customers for infectious disease screening.
Diagnostics - Self-Test12% At-home and self-administered infectious disease tests sold through retail and distribution channels.
Sample Management Solutions25% Specimen collection and sample handling products for clinical, research, and commercial labs.
Other Products and Services5% Smaller product lines and service revenues, including research-use devices and related services.

OraSure sells to a mix of public health agencies, hospitals, physician offices, clinics, distributors, and retail...

  • Public health agencies and programsprimary

    Buy HIV, HCV, and other infectious disease tests for screening and outreach programs.

  • Hospitals, clinics, and physician officesprimary

    Buy rapid diagnostic tests for point-of-care infectious disease testing.

  • Distributors and retail channelssecondary

    Buy self-test products and resell them into consumer and institutional markets.

  • Clinical and direct-to-consumer laboratoriesprimary

    Buy sample collection and management products for testing workflows.

  • Research, biotech, and pharmaceutical customerssecondary

    Buy specimen collection devices and related products for studies and assay development.

  • Animal health and companion animal customersemerging

    Buy sample management products for veterinary and animal-health applications.

OraSure markets products in the United States and internationally, with U.S. public health and clinical customers...

  • •United States is the core market for diagnostics and public health sales
  • •International HIV demand is important for self-tests and distributor sales
  • •Africa and Asia are key exposure areas for funded HIV programs
  • •Canada houses a meaningful portion of cash and liquidity resources
  • •Distributor networks extend reach in foreign markets and retail channels

OraSure’s strategy centers on expanding simple, easy-to-use diagnostics and specimen-collection products across...

01
Grow self-testing and point-of-care diagnosticsmedium-term

These products fit the company's ease-of-use positioning and broaden end-market reach.

02
Secure regulatory clearances for new productsshort-term

FDA and other approvals are required to commercialize new diagnostic offerings.

03
Expand distributor and public health channelsmedium-term

Distribution access is critical in fragmented diagnostics markets and international sales.

04
Develop sample management and collection productslong-term

These products diversify the portfolio beyond infectious disease testing.

OraSure faces regulatory, reimbursement, and competitive risks typical of diagnostics companies, along with customer...

high

Regulatory approval and compliance risk

New diagnostics require FDA or other clearances, and noncompliance can halt sales or trigger recalls.

Scope
New products and existing regulated tests
Materiality
high
high

Government funding and ordering risk

A meaningful portion of demand depends on public programs and grant-funded customers.

Scope
HIV and public health testing markets
Materiality
high
high

Manufacturing and quality risk

Products must meet performance and regulatory standards to remain sellable.

Scope
All diagnostic and collection products
Materiality
high
medium

Customer concentration

A small number of customers can represent a disproportionate share of revenue.

Scope
Large distributors and institutional buyers
Materiality
medium
medium

Distributor dependence

Third-party distributors control sales execution in several markets and geographies.

Scope
International and retail channels
Materiality
medium
medium

Competition in diagnostics

Larger competitors have greater resources and can pressure pricing and market share.

Scope
Rapid tests and sample collection products
Materiality
high
Revenue recognition for product sales
Quarterly revenue comparability
Returns and warranty reserves
Net revenue and gross margin
Goodwill and intangible impairment
Earnings and balance sheet carrying values
Fair value of contingent consideration
Operating results
Allowance and rebate estimates
Reported net sales

ORASURE TECHNOLOGIES INC

OSUR · Surgical & Medical Instruments & Apparatus

MEKO

MEKO.ST · Consumer Discretionary

New Wave

NEWA-B.ST · Consumer Discretionary

Bufab

BUFAB.ST · Industrials

Hexatronic Group

HTRO.ST · Telecommunications

Apotea

APOTEA.ST · Consumer Staples

: 29/04/2026